Wegovy (injectable)
Growing slowly in Q2 2026 as the oral Wegovy pill takes new patients.
The numbers
What it is
Weekly semaglutide injection for chronic weight management. It is the flagship obesity product and the reference point for the whole GLP-1 weight-loss market.
Why it matters to the stock. Wegovy injectable sales are the main test of whether volume growth can offset lower prices in the US. A slowdown here moves the whole stock.
News
Novo Nordisk Q2 2026 profit beats forecasts and raises full-year outlook
Novo reported Q2 2026 adjusted sales of DKK 78,488 million, up 7% at constant exchange rates, and adjusted operating profit of DKK 33,389 million, up 11%.
Novo Nordisk Q1 adjusted sales fall 4% at CER; 2026 outlook raised to -4% to -12%
Novo Nordisk reported first-quarter reported sales of DKK 96.8 billion, inflated by the USD 4.2 billion 340B reversal.
Wegovy HD (7.2 mg) launches in the US in a single-dose pen
Novo Nordisk launched Wegovy HD, the 7.2 mg weekly injection, in the US in April 2026, after the March FDA approval.
Novo Nordisk reverses a USD 4.2 billion 340B provision, excluded from adjusted results
Novo Nordisk reversed a provision of USD 4.2 billion linked to the US 340B Drug Pricing Program, recorded in the first quarter of 2026.